Skadden, Arps, Slate, Meagher & Flom has advised Japan’s Nippon Shokubai on its acquisition of Sirrus, a U.S.-based chemical company, which was represented by Cooley. The financial terms of the transaction were not disclosed. 

Founded as Bioformix in 2009, Sirrus has built a portfolio of more than 25 global patents that address process technologies, methods of application, initiation, formulation and stabilisation, as well as composition of matter for certain polymers. 

“Combined with Sirrus’ intellectual property position, track record of innovation, and access to a broad range of customers and applications, the transaction is a strong strategic fit for Nippon Shokubai,” said Masanori Ikeda, the Japanese chemical giant’s president, in a statement.  

The Skadden team was led by partners Mitsuhiro Kamiya, Michael Mies and Resa Schlossberg.

Related Articles

Deals

Skadden, Jia Yuan, Freshies, KWM act on Midea’s $3.5 bln HK share offering

by Asian Legal Business《亚洲法律杂志》 |

Skadden, Arps, Slate, Meagher & Flom and Jia Yuan Law Offices are advising Chinese home appliance maker Midea Group on its HK$26.97 billion ($3.46 billion) share offering in Hong Kong, the city's largest listing in more than three years.

Deals

Skadden, STB advise on Timee’s $435mln Japan IPO

by Nimitt Dixit |

U.S. law firm Skadden, Arps, Slate, Meagher & Flom has guided Timee, Inc, a Japanese on-demand job platform, on its $435 million initial public offering and listing on the Tokyo Stock Exchange. Simpson Thacher & Bartlett advised the international managers on the deal.

Deals

Skadden, Latham act on $1.1 bln Japan outbound pharma deal

by Asian Legal Business《亚洲法律杂志》 |

Skadden, Arps, Slate, Meagher & Flom has advised Japan's Otsuka Pharmaceutical on its $1.1 billion agreement to acquire Boston-based Jnana Therapeutics, which was represented by Latham & Watkins.